Alto Neuroscience, Return On Equity vs. Cash Flow From Operations
| ANRO Stock | 3.89 0.16 3.95% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter 0.5065437 | Current Value 0.72 | Quarterly Volatility 0.05899023 |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.25 | 0.28 |
|
| |||||
| Return On Equity | 0.72 | 0.5065 |
|
|
For Alto Neuroscience, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Alto Neuroscience, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Alto Neuroscience, utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Alto Neuroscience,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Alto Neuroscience, over time as well as its relative position and ranking within its peers.
Alto |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alto Neuroscience,. If investors know Alto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alto Neuroscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.38) | Return On Assets (0.32) | Return On Equity (0.57) |
The market value of Alto Neuroscience, is measured differently than its book value, which is the value of Alto that is recorded on the company's balance sheet. Investors also form their own opinion of Alto Neuroscience,'s value that differs from its market value or its book value, called intrinsic value, which is Alto Neuroscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alto Neuroscience,'s market value can be influenced by many factors that don't directly affect Alto Neuroscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alto Neuroscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Alto Neuroscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alto Neuroscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Alto Neuroscience, Cash Flow From Operations vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Alto Neuroscience,'s current stock value. Our valuation model uses many indicators to compare Alto Neuroscience, value to that of its competitors to determine the firm's financial worth. Alto Neuroscience, is rated below average in return on equity category among its peers. It is rated below average in cash flow from operations category among its peers . At this time, Alto Neuroscience,'s Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Alto Neuroscience,'s earnings, one of the primary drivers of an investment's value.Alto Cash Flow From Operations vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Alto Neuroscience, |
| = | -0.57 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Alto Neuroscience, |
| = | (33.45 M) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Alto Cash Flow From Operations Comparison
Alto Neuroscience, is currently under evaluation in cash flow from operations category among its peers.
Alto Neuroscience, Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Alto Neuroscience,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Alto Neuroscience, will eventually generate negative long term returns. The profitability progress is the general direction of Alto Neuroscience,'s change in net profit over the period of time. It can combine multiple indicators of Alto Neuroscience,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -71.1 K | -74.7 K | |
| Net Interest Income | 1.1 M | 1.2 M | |
| Interest Income | 2.7 M | 2.8 M | |
| Operating Income | -34 M | -35.7 M | |
| Net Loss | -32.7 M | -34.3 M | |
| Income Before Tax | -32.7 M | -34.3 M | |
| Total Other Income Expense Net | 1.4 M | 1.6 M | |
| Net Loss | -32.7 M | -34.3 M | |
| Net Loss | (1.35) | (1.42) | |
| Income Quality | 0.92 | 0.98 |
Alto Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Alto Neuroscience,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Alto Neuroscience, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Alto Neuroscience,'s important profitability drivers and their relationship over time.
Use Alto Neuroscience, in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alto Neuroscience, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alto Neuroscience, will appreciate offsetting losses from the drop in the long position's value.Alto Neuroscience, Pair Trading
Alto Neuroscience, Pair Trading Analysis
The ability to find closely correlated positions to Alto Neuroscience, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alto Neuroscience, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alto Neuroscience, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alto Neuroscience, to buy it.
The correlation of Alto Neuroscience, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alto Neuroscience, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alto Neuroscience, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alto Neuroscience, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Alto Neuroscience, position
In addition to having Alto Neuroscience, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corporate ETFs Thematic Idea Now
Corporate ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Corporate ETFs theme has 223 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience, guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
To fully project Alto Neuroscience,'s future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Alto Neuroscience, at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Alto Neuroscience,'s income statement, its balance sheet, and the statement of cash flows.